Nab-Paclitaxel Combined With Gemcitabine Adjuvant Chemotherapy After Radical Resection of Intrahepatic Cholangiocarcinoma

Inclusion Criteria: 1. The patient must have good compliance, be understood the research process of this study and required to sign an informed consent form; 2. age 18-75 years old, male or female; 3. Histopathologically confirmed intrahepatic cholangiocarcinoma，excluding mixed liver cancer; 4. The longest diameter of a single tumor in patients before surgery is 3\~9cm. If the number of multiple tumors is ≤3, the total diameter≤9cm, maximum diameter ≤5cm; 5. Study treatment can be started within 4\~6 weeks after R0 resection; 6. Except for R0 resection, no other anti-tumor treatment has been received; 7. No distant transfer； 8. ECOG\<2, or KPS\>70； 9. Bone marrow function criteria: hemoglobin (HGB)≥90g/L; absolute neutrophil count (ANC)≥1.5×109/L; platelets (PLT)≥100×109/L; 10. Liver function criteria: ALT, AST≤5×ULN, serum total bilirubin\<3×ULN; 11. Renal function criteria: creatinine clearance \> 45 mL/min 12. Prothrombin time \<14s; (no anticoagulant therapy); 13. Patients without biliary obstruction who require biliary stent implantation must be completed at least 7 days prior to enrollment; 14. Non-lactating or pregnant women, contraception during or after 6 months of treatment. 15. No contraindications for gemcitabine and Nab-paclitaxel. Exclusion Criteria: 1. Those patients who are allergic to the chemotherapy drugs and their components in this study 2. Patients with other malignant tumors within 5 years (except for cured carcinoma in situ or basal cell carcinoma of the skin) 3. Concomitant diseases that may interfere with treatment studies: such as severe infections, HIV-positive, clinically severe (ie active) Heart disease, uncontrolled epilepsy, central nervous system disease, or history of mental disorders; 4. Intraoperative or postoperative pathology determines patients who do not meet radical resection; 5. Patients with current or previous ≥ grade II peripheral neuropathy; 6. Patients who participated in other clinical studies within 4 weeks prior to enrollment; 7. Patients who has undergone organ transplantation; 8. Patients considered by the investigator not suitable for this trial.